Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.62 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.62 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.62 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.62 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.62 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.62 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.62 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.62 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.62 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.62 |
| ▸ | EDNRA known ✓ | P25101 | 1/20 | 0.62 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.62 |
| ▸ | AVPR2 known ✓ | P30518 | 1/20 | 0.62 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.62 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.62 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.62 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.62 |
| ▸ | AVPR1A known ✓ | P37288 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881349 | 0.99 | NPC1 (0.63) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| Hydrochloric Acid SCHEMBL1392668 | 0.90 | NPC1 (0.69) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL10253193 | 0.90 | MEN1 (0.66) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL10286970 | 0.88 | STAT3 (0.61) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL375723 | 0.84 | MEN1 (0.71) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL17732539 | 0.83 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2APKM | |
| SCHEMBL2856743 | 0.83 | NPC1 (0.77) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL376119 | 0.83 | MEN1 (0.67) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL375422 | 0.83 | STAT3 (0.57) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL27134627 | 0.81 | MEN1 (0.76) | NPC1RAB9AMEN1KMT2ASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632460-B1 | THIOPHENE DERIVATIVES FOR USE IN THE TREATMENT OF TUBERCULOSIS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2408770-B1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | Univ Virginia Patent Found (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130317070-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2632460-A2 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | University Of Virginia Patent Foundation (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012040170-A2 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-2408770-A2 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | University Of Virginia Patent Foundation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010107736-A2 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317070-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | NRDC, TST, TBCD | ADRB2 2845/4885CHRM2 4124/4885ADRB1 2080/4885 |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | NMT1, MLEC, EPN1 | ADRB2 4142/4885CHRM2 4719/4885ADRB1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.